Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
- Author(s)
- Luen, SJ; Viale, G; Nik-Zainal, S; Savas, P; Kammler, R; Dell'Orto, P; Biasi, O; Degasperi, A; Brown, LC; Lang, I; MacGrogan, G; Tondini, C; Bellet, M; Villa, F; Bernardo, A; Ciruelos, E; Karlsson, P; Neven, P; Climent, M; Muller, B; Jochum, W; Bonnefoi, H; Martino, S; Davidson, NE; Geyer, C; Chia, SK; Ingle, JN; Coleman, R; Solbach, C; Thurlimann, B; Colleoni, M; Coates, AS; Goldhirsch, A; Fleming, GF; Francis, PA; Speed, TP; Regan, MM; Loi, S;
- Details
- Publication Year 2023-04,Volume 34,Issue #4,Page 397-409
- Journal Title
- Annals of Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. PATIENTS AND METHODS: Genomic sequencing was applied to HR+HER2- tumours from patients enrolled in the Suppression of Ovarian Function Trial (SOFT) to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample, n = 82). We defined copy number (CN) subgroups and assessed for features suggestive of homologous recombination deficiency (HRD). Genomic alteration frequencies were compared between young premenopausal women (<40 years) and older premenopausal women (>/=40 years), and assessed for associations with distant recurrence-free interval (DRFI) and overall survival (OS). RESULTS: Younger women (<40 years, n = 359) compared with older women (>/=40 years, n = 917) had significantly higher frequencies of mutations in GATA3 (19% versus 16%) and CN amplifications (CNAs) (47% versus 26%), but significantly lower frequencies of mutations in PIK3CA (32% versus 47%), CDH1 (3% versus 9%), and MAP3K1 (7% versus 12%). Additionally, they had significantly higher frequencies of features suggestive of HRD (27% versus 21%) and a higher proportion of PIK3CA mutations with concurrent CNAs (23% versus 11%). Genomic features suggestive of HRD, PIK3CA mutations with CNAs, and CNAs were associated with significantly worse DRFI and OS compared with those without these features. These poor prognostic features were enriched in younger patients: present in 72% of patients aged <35 years, 54% aged 35-39 years, and 40% aged >/=40 years. Poor prognostic features [n = 584 (46%)] versus none [n = 692 (54%)] had an 8-year DRFI of 84% versus 94% and OS of 88% versus 96%. Younger women (<40 years) had the poorest outcomes: 8-year DRFI 74% versus 85% and OS 80% versus 93%, respectively. CONCLUSION: These results provide insights into genomic alterations that are enriched in young women with HR+HER2- EBC, provide rationale for genomic subgrouping, and highlight priority molecular targets for future clinical trials.
- Publisher
- Elsevier
- Keywords
- Humans; Female; Aged; *Breast Neoplasms/drug therapy; Receptor, ErbB-2/metabolism; Prognosis; Genomics; Class I Phosphatidylinositol 3-Kinases/genetics; breast cancer; hormone receptor positive; young women
- Department(s)
- Medical Oncology
- PubMed ID
- 36709040
- Publisher's Version
- https://doi.org/10.1016/j.annonc.2023.01.009
- Open Access at Publisher's Site
10.1016/j.annonc.2023.01.009- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-27 08:03:05
Last Modified: 2024-07-10 08:23:50